Bernstein lifts price targets on LRCX and KLAX after lifting WFE forecasts

Bernstein raised its 2026/2027/2028 global wafer fabrication equipment spending forecasts to $148B, $175B, and $198B, respectively, implying a near-$200B WFE market within sight. The upgrade was driven by stronger memory capex, especially DRAM, and higher China demand tied to YMTC and CXMT expansion plans. Price targets were lifted on Lam Research to $340 from $325 and on KLA to $1,975 from $1,875, while Applied Materials' $525 target was unchanged.

Analysis

The market is likely underestimating how quickly this turns from a discrete WFE upgrade into a broader earnings-duration event. If memory capex is reaccelerating first, the second-order beneficiaries are the consumables-heavy and installed-base names with the highest operating leverage to utilization, not just the headline OEMs; that argues for a wider read-through across etch, deposition, metrology, and process control as fab starts normalize. The more important signal is that China is being treated as a structural demand source again, which reduces the probability that the current equipment upcycle is a one- or two-quarter pop.

The main risk is that investors extrapolate the capex revision linearly while memory pricing remains the actual gating variable. If DRAM pricing rolls over before capacity additions are fully absorbed, wafer starts can be pushed out even as budgets look strong on paper, creating a 6-12 month disappointment window for equipment orders. A softer but still material risk is mix: if spending shifts toward mature-node and incremental yield work rather than leading-edge logic, the multiple expansion case compresses for the highest-expectation names.

The contrarian read is that the best risk/reward may not be the most obvious “best-in-class” name if the market has already priced in AI-led leading-edge strength. A multi-year WFE cycle with China participation tends to favor the broader basket and the most levered operating model, especially where consensus margins are still conservative. In that setup, the market may be too focused on endpoint TAM and not enough on the path of revisions, which usually matters more for stock performance over the next 3-9 months.

Key Decisions for Investors

• Long LRCX on a 3-6 month horizon; use the revised WFE trend as a valuation support thesis, with upside if memory capex keeps getting revised higher. Risk: if DRAM pricing softens, the order multiple can de-rate quickly.
• Buy AMAT on pullbacks and prefer it as the core long in the group for a 6-12 month window; it has the best blend of exposure and relative resilience if capex broadens beyond memory. Best risk/reward if the market starts rewarding breadth over pure AI enthusiasm.
• Pair long LRCX / short a software or semi name with little WFE sensitivity over the next 1-2 quarters to isolate the capex revision trade. The goal is to capture the revision cycle without taking full beta.
• Consider KLAC as a tactical long only if you expect spending to migrate toward process control and yield optimization; otherwise it is the cleanest candidate for mean reversion if the market overpays for the upgrade.
• For options, use 3-6 month call spreads on AMAT or LRCX to express upside while capping theta risk if the WFE upgrade narrative stalls before order data confirms it.